Cite

HARVARD Citation

    Benderradji, H. et al. (2022). Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month. Clinical endocrinology. pp. 52-63. [Online]. 
  
Back to record